The University of Edinburgh analyzed more than 6,000 genomes in a year, an effort made possible by a computing center dubbed a "genome factory" by its director.
Pacific Biosciences reported total Q1 2017 revenues of $24.9 million, just beating analysts' average estimate of $24.6 million.
The team's assembly represents 95 percent of the genomic sequence of barley, the most complete version of that genome to date.
The two studies came out of the UK's Tracking Cancer Evolution through Therapy (TRACERx) trial.
Illumina's NovaSeq accessory, which it plans to launch in Q4, will enable customers to run different experiments and library types in different flow cell lanes.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.
This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.
This webinar will provide an overview of an RNA-seq protocol that has been optimized to study small RNA species such as microRNAs.
This webinar will discuss a target enrichment workflow for high-confidence detection of variants.
This webinar will discuss RNA sequencing as an alternative to immunohistochemistry (IHC) in selecting patients for cancer immunotherapy.